GLP-1 drugs and addiction: they stop cravings from forming

Patients taking GLP-1 medications for diabetes started reporting something unexpected a few years ago: they stopped wanting alcohol. Or cigarettes. Or, in some cases, both. Clinicians noticed. Researchers followed. What they found goes well beyond appetite suppression.

The study that changed the conversation

In March 2026, a team at Washington University School of Medicine in St. Louis published findings in The BMJ from one of the largest studies ever conducted on GLP-1 medications and addiction. The dataset: electronic health records from 606,434 U.S. veterans with type 2 diabetes, tracked for up to three years.

The researchers compared two groups - those taking GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and those taking SGLT-2 inhibitors, another class of diabetes medication. Crucially, they split the analysis into two populations: those with no pre-existing substance use disorder, and those already struggling with one.

Lead researcher Dr. Ziyad Al-Aly, a clinical epidemiologist at WashU Medicine and the VA Saint Louis Health Care System, had watched this unfold in real time at his clinic. Patients would mention, almost as an aside, that they hadn't felt like drinking since starting their GLP-1 medication. "This is not a story about only nicotine or alcohol or heroin or cocaine or opiates," Al-Aly told reporters. "It's all of them."

The prevention finding - and why it matters

Among the 524,817 participants without pre-existing substance use disorders, people taking GLP-1 medications were significantly less likely to develop an addiction compared to those taking SGLT-2 inhibitors:

• 14% lower risk of developing any substance use disorder overall
• 18% reduction for alcohol use disorder
• 14% reduction for cannabis use disorder
• 20% reduction for cocaine and nicotine use disorders
• 25% reduction for opioid use disorder
• Translated to population numbers: 7 fewer new substance use disorder diagnoses per 1,000 GLP-1 users

This is the prevention angle - and it is what makes the National Geographic coverage of this research so striking. As science journalist Emily Sohn reported in March 2026, these drugs do not just quiet existing cravings. They appear to stop new addiction pathways from forming in the first place.

Al-Aly's theory centres on what he calls reducing "drug noise" - analogous to how GLP-1 medications quiet "food noise" (the constant background rumination about eating that many obese patients describe). People who use GLP-1 medications for weight loss often report that food stops being something they think about constantly. The same mechanism, Al-Aly proposes, may apply to other reward-seeking behaviours driven by the same neural circuitry.

Harm reduction in people already struggling

Among the 81,617 participants who already had a substance use disorder, the findings were just as compelling:

• 30% reduction in emergency department visits related to substance use
• 25% reduction in hospitalizations
• 40% reduction in overdose events
• 50% reduction in drug-related deaths
• 25% reduction in suicidal ideation or attempts
• Translated to population impact: 12 fewer serious harm events per 1,000 GLP-1 users

A 50% reduction in drug-related deaths is not a rounding error. That is a signal of the magnitude usually associated with the most effective interventions in addiction medicine. For context, naloxone (Narcan) reverses opioid overdoses acutely - it is a life-saving intervention but does not address underlying addiction. Methadone and buprenorphine reduce opioid use disorder effectively, but each targets one substance. GLP-1 medications, if these findings hold in broader populations, would be the first class of drugs to show protective effects across all major addictive substances simultaneously.

How the biology works

GLP-1 receptors are not only in the gut and pancreas. They cluster in regions of the brain that govern reward processing, motivation, impulse control, and stress response - the same circuits that addiction hijacks.

Animal studies have consistently shown that GLP-1 receptor activation reduces dopamine release in the nucleus accumbens (the brain's primary reward centre) in response to addictive substances - alcohol, nicotine, cocaine, opioids. Less dopamine release means a weaker reward signal. A weaker reward signal means the substance is less compelling, less memorable, less worth seeking.

Dr. Anna Lembke, an addiction medicine specialist at Stanford University, described the pattern to National Geographic as a "global constraint on appetite" - not just for food, but for reward-seeking behaviour more broadly. She was careful to note that effectiveness varies considerably between individuals, and that GLP-1 medications should not yet be positioned as first-line addiction treatments. But she called the development "a welcome advancement for addiction treatment options" - a field that has historically had very few tools and high relapse rates.

What remains unknown

The honesty of the research is one of its strengths. Several important unknowns were flagged directly by the investigators:

• High discontinuation rates: the same 70% dropout pattern seen in weight loss contexts applies here. If the benefit depends on staying on the medication, what happens when you stop?
• Relapse patterns after stopping: Al-Aly posed the question directly: "Do addiction or cravings come back with a vengeance?" Initial evidence from the food-noise analogy suggests appetite suppression returns when GLP-1 medications are stopped. Whether addiction cravings follow the same trajectory is not yet studied.
• Veteran population generalisability: the VA study was conducted almost entirely in older male veterans, a population with specific health profiles and substance use patterns. Whether findings translate to women, younger adults, and non-veteran populations requires dedicated research.
• Side effects in addiction contexts: nausea, fatigue, and GI symptoms are common GLP-1 side effects. In patients already managing substance use disorder, these may affect adherence differently than in metabolic patients.

More than a dozen clinical trials are already underway or actively enrolling to test GLP-1 medications specifically for addiction. One trial added weekly semaglutide to cognitive behavioural therapy for alcohol use disorder and found it further reduced heavy drinking - the first controlled evidence of the effect in that context.

What this means if you are on a GLP-1 medication

If you are taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for weight loss or diabetes, you may already have noticed changes in your relationship with alcohol, cigarettes, or other substances. You are not imagining it. The biology is real.

This does not mean GLP-1 medications are a treatment for addiction - that clinical designation requires controlled trials that are still running. But the epidemiological signal from 600,000 patients is hard to dismiss. These drugs appear to do something meaningful to the reward system that extends well beyond food.

One thing worth noting: the nutrient depletion that comes with significantly reduced food intake on GLP-1 medications can affect brain chemistry, mood, and energy in ways that may complicate both weight loss and overall well-being. Ensuring adequate intake of vitamins B12, D, magnesium, and protein is part of keeping your system functioning well while on these medications. GLP-1 Shield was designed to address exactly that nutritional gap.

Frequently asked questions

Can GLP-1 medications help with alcohol or drug addiction?

Early research - including a March 2026 BMJ study of 606,434 veterans - found that people taking GLP-1 medications had 14-25% lower rates of developing substance use disorders and 40-50% fewer overdose events and drug-related deaths compared to those on other diabetes medications. This is promising but GLP-1 drugs are not yet approved for addiction treatment, and clinical trials are still running.

Why do GLP-1 drugs reduce cravings for alcohol and other substances?

GLP-1 receptors cluster in brain regions governing reward, motivation, and impulse control - the same circuits involved in addiction. GLP-1 receptor activation appears to reduce dopamine signalling in response to addictive substances, making rewards feel less compelling. Researchers describe this as reducing "drug noise" in the same way the medications reduce "food noise" in people with obesity.

Does Ozempic stop you wanting to drink alcohol?

Many patients report reduced desire for alcohol after starting semaglutide (Ozempic, Wegovy). The large 2026 VA study found an 18% reduced risk of developing alcohol use disorder in GLP-1 users compared to those on other diabetes medications. Individual responses vary considerably - some people notice this effect strongly, others less so.

What happens to addiction cravings when you stop taking GLP-1 medications?

This is currently an open question. Researchers have noted that appetite returns when GLP-1 medications are stopped - whether addiction cravings follow the same pattern is not yet well studied. It is a critical question for clinical practice, and investigators have flagged it explicitly as a priority for ongoing research.